iVIEW Therapeutics
- Biotech or pharma, therapeutic R&D
iView Therapeutics is a clinical-stage Ophthalmology focused biotechnology company based in Cranbury, New Jersey. Lead assets cover Dry eye, Infectious Conjunctivitis, Myopia, and Glaucoma gene therapy. The lead program, a novel TRPM8 agonist, IVW-1001 Eyelid wipe has achieved statistically significant improvement in key sign and symptom of dry eye patients, including corneal fluorescein staining and SANDE scores, in the phase 2a clinical trials in the US. IVIEW is advancing the program to pivotal phase 3 clinical trials in early 2026. The second lead program, IVIEW-1201D/IVIEW-1201, novel sustain release in-situ gel forming compositions containing a broad spectrum antiseptic, povidone iodine, are moving ahead into phase 3 clinical development for viral conjunctivitis. Iview Therapeutics is interested in out-licensing, co-development for phase 3 trials and commercialization, and investment for B round financing.
Address
CranburyNew Jersey
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}